Category: Corporate NewsBy adminJune 15, 2022 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Disclosure to EGX regarding molecule acquisitionNextNext post:Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. commences the production of antiviral COVID-19 treatment, Molnupiravir RamedaRelated PostsRameda Initiates First Acquisition of 2025July 7, 2025Record Dividend Distribution DisclosureJuly 7, 2025Rameda One-Pager 1Q25May 13, 2025Earnings Release One-Pager 4Q24March 10, 2025Earning Release One Pager 3Q24November 14, 2024Rameda Completes Largest Acquisition to DateSeptember 30, 2024
